Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Roxee Meds Catalog

Triamcinolone Acetonide

Medication catalog facts with explicit FDA-approval, off-label, source-limited, and safety context.

Both Catalog complete FDA data linked Rx required Tablet Multiple FDA labelers Official label facts Owner quick guide first
Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Storefront facts
Catalog refreshed
May 5, 2026, 10:00 a.m.

These are the storefront facts Roxee uses on browse cards and quick facts.

FDA applications
FDA application data refreshed
May 5, 2026, 10:00 a.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports
Safety data refreshed
May 5, 2026, 10:01 a.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Storefront facts: Source Roxee | Refreshed May 5, 2026, 10:00 AM UTC
    The storefront fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC

Evidence

Reviewed / Updated / Sources

Reviewed by: Not available

Last reviewed: February 12, 2026

Updated: February 12, 2026, 10:44 PM UTC

Sources:
Image coming soon
Triamcinolone Acetonide

Triamcinolone Acetonide

Drug type: Generic ingredient • Branded profile • FDA branded products available

Both Tablet Rx required 100% storefront ready

Species: Both

Manufacturer: Multiple FDA labelers

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Triamcinolone Acetonide

Treatment of inflammation and related disorders in dogs; and management and treatment of acute arthritis and allergic and dermatologic disorders in dogs. Treatment of inflammation and related disorders in horses. Treatment of inflammation and related disorders in cats; and management and treatment of acute arthritis and allergic and dermatologic disorders in cats. Species commonly shown: Both, Dog, No Use Class Stated Or Implied, Cat, No Use Class Stated Or Implied.

Generic name
Triamcinolone Acetonide
Brand names
Triamcinolone Acetonide, Vetalog Oral Powder, Triamcinolone Acetonide Suspension, Genesis® Topical Spray
Manufacturer
Multiple FDA labelers
Species
Both, Dog, No Use Class Stated Or Implied, Cat, No Use Class Stated Or Implied, Horse, Not For Meat Production
Dosage forms
Tablet, Powder, Liquid (Suspension), Liquid (Solution)
Prescription
Prescription required
Completeness
100%
Validation
Complete
Brand names
Triamcinolone Acetonide Vetalog Oral Powder Triamcinolone Acetonide Suspension Genesis® Topical Spray Medalone Cream Vetalog® VETAZINE Vetalog® Parenteral Vetalog Cream Genesis
Dosage forms
Tablet Powder Liquid (Suspension) Liquid (Solution) Cream

Indications / Uses

Treatment of inflammation and related disorders in dogs; and management and treatment of acute arthritis and allergic and dermatologic disorders in dogs. Treatment of inflammation and related disorders in horses. Treatment of inflammation and related disorders in cats; and management and treatment of acute arthritis and allergic and dermatologic disorders in cats.

Warnings / Contraindications

Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Do not use in horses intended for human consumption. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Do not use in the treatment of laminitis. Intra-articular injection in equine leg injuries may produce osseous metaplasia. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For mild inflammations, use once daily to once a week. For severe conditions, apply initially two to three times daily, decreasing frequency as improvement occurs. Not intended for treatment of deep abscesses or deep-seated infections. Not for ophthalmic use. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Do not use in horses intended for human consumption. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Do not use in the treatment of laminitis. Intra-articular injection in equine leg injuries may produce osseous metaplasia. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For mild inflammations, use once daily to once a week. For severe conditions, apply initially two to three times daily, decreasing frequency as improvement occurs. Not intended for treatment of deep abscesses or deep-seated infections. Not for ophthalmic use. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Side Effects

Top reported reactions (openFDA): Deafness, Loss of hearing, Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Lack of efficacy - NOS, Diarrhoea.

FAQ

Both, Dog, No Use Class Stated Or Implied, Cat, No Use Class Stated Or Implied, Horse, Not For Meat Production, Dog, Restricted During Pregnancy, Cat, Restricted During Pregnancy, No Use Class Stated Or Implied

Yes. Roxee shows this as prescription-only.

Tablet, Powder, Liquid (Suspension), Liquid (Solution)

Related Conditions

Dystocia Metritis Pica Pruritus (itching, undifferentiated)

Source Transparency

Add to My Pet's Meds

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

The drug is recommended for use on dogs as an anti-inflammatory, antipruritic, and antiallergic agent for topical treatment of allergic dermatitis and summer eczema.

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • Do not use in viral infections
  • With bacterial infections appropriate antibacterial therapy should be used
  • Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy
  • Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis
  • Do not use in horses intended for human consumption
  • Do not use in the treatment of laminitis
  • Intra-articular injection in equine leg injuries may produce osseous metaplasia
  • For mild inflammations, use once daily to once a week
  • For severe conditions, apply initially two to three times daily, decreasing frequency as improvement occurs
  • Not intended for treatment of deep abscesses or deep-seated infections
  • Not for ophthalmic use
  • very low energy (1 reports)
  • Miosis (1 reports)
  • Medication error NOS (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?
Major cautions & emergency warning signs

Side effects to monitor:

  • Do not use in viral infections
  • With bacterial infections appropriate antibacterial therapy should be used
  • Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy
  • Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis
  • Do not use in horses intended for human consumption

Most reported reactions:

  • Tiredness (lethargy) (1 reports)
  • Miosis (1 reports)
  • Medication error NOS (1 reports)

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Multiple FDA labelers
Form: Cream, Liquid (Solution), Liquid (Suspension), Powder, Tablet
Identifiers:
ANADA: 200245 ANADA: 200275 ANADA: 200330 ANADA: 200459 NADA: 12198 NADA: 12258 NADA: 13624 NADA: 137694 NADA: 138869 NADA: 140810 NADA: 140847 NADA: 140879 NADA: 140889 NADA: 141003 NADA: 141210 NADA: 30045 NADA: 46146 NADA: 96676 NADA: 99388 NDC Package: 17033-122-15
Source metadata:

Warnings / Contraindications

Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Do not use in horses intended for human consumption. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Do not use in the treatment of laminitis. Intra-articular injection in equine leg injuries may produce osseous metaplasia. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For mild inflammations, use once daily to once a week. For severe conditions, apply initially two to three times daily, decreasing frequency as improvement occurs. Not intended for treatment of deep abscesses or deep-seated infections. Not for ophthalmic use. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • High: Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Do not use in horses intended for human consumption. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Do not use in the treatment of laminitis. Intra-articular injection in equine leg injuries may produce osseous metaplasia. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For mild inflammations, use once daily to once a week. For severe conditions, apply initially two to three times daily, decreasing frequency as improvement occurs. Not intended for treatment of deep abscesses or deep-seated infections. Not for ophthalmic use. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
21
Species represented
2
Grouped by Body System
Digestive (4) · Vomiting, Drooling, Diarrhea Skin & allergy (1) · Localised hair loss Neurologic (2) · Tiredness (lethargy), Head tilt - neurological disorder Behavior (2) · Head shake - behavioural disorder, Behavioral disorder (unspecified) Effectiveness (1) · Lack of efficacy - NOS Other (22) · Moist dermatitis, Miosis, Medication error NOS
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Neurologic 1 Cat 1
Other 1 Cat 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Cat 1
Behavior 1 Cat 1
Other 1 Dog 1
Other 1 Cat 1

Species coverage: Dog (18) Cat (14)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Digestive Cat Non-serious - 1
Neurologic Cat Serious - 1
Other Dog Non-serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Skin & allergy Dog Non-serious - 1
Other Dog Non-serious - 1
Effectiveness Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Cat Serious - 1
Neurologic Cat Non-serious - 1
Behavior Cat Serious - 1
Other Dog Serious - 1
Other Cat Non-serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Digestive Dog Serious - 1
Digestive Cat Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Behavior Cat Serious - 1
Other Dog Serious - 1
Digestive Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Source metadata:

Documents

Owner handouts and official technical documents open on-page first, with the original source still one click away.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

0
No official label or package insert links yet.

SPL

11

FOI

8

Medalone Cream

SPL · SPL

Open original
FDA Structured Product Label

Medalone Cream

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Med-Pharmex, Inc.
ANADA
200-275
Status
RX
Form
Cream
Route
Topical
Species
Dog, No Use Class Stated Or Implied
Composition / specifications
Triamcinolone acetonide cream contains 0.1 percent triamcinolone acetonide in an aqueous vanishing cream base.

Dogs

Indication
The drug is recommended for use on dogs as an anti-inflammatory, antipruritic, and antiallergic agent for topical treatment of allergic dermatitis and summer eczema.
Dosage
The drug is applied by rubbing into affected areas two to four times daily for 4 to 10 days.
Limitations
For use only by or on the order of a licensed veterinarian.

Triamcinolone Acetonide

SPL · SPL

Open original
FDA Structured Product Label

Triamcinolone Acetonide

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Boehringer Ingelheim Animal Health USA Inc.
NADA
13624
Status
RX
Form
Tablet
Route
Oral
Species
Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
Each tablet contains 0.5 and 1.5 milligrams of the drug.

Dogs

Indication
The drug is indicated for use in dogs for its anti-inflammatory activity.
Dosage
An initial daily dosage of 0.05 milligram per pound of body weight is usually sufficient to control symptoms, although up to 0.1 milligram per pound of body weight may be given daily if response to the smaller dose is inadequate. As soon as feasible, and in any case within 2 weeks, dosage should be reduced gradually to maintenance levels of 0.0125 to 0.025 milligram per pound of body weight per day. Therapy should be discontinued by a gradual reduction in dosage after the condition has been controlled for several days. Therapy may be initiated with a single dose of sterile triamcinolone acetonide suspension veterinary in which case the tablet dosage should be administered beginning 5 to 7 days after the injection or when symptoms reappear.
Limitations
The labeling shall comply with the requirements of 510.410 of this chapter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Cats

Indication
The drug is indicated for use in cats for its anti-inflammatory activity.
Dosage
An initial daily dosage of 0.05 milligram per pound of body weight is usually sufficient to control symptoms, although up to 0.1 milligram per pound of body weight may be given daily if response to the smaller dose is inadequate. As soon as feasible, and in any case within 2 weeks, dosage should be reduced gradually to maintenance levels of 0.0125 to 0.025 milligram per pound of body weight per day. Therapy should be discontinued by a gradual reduction in dosage after the condition has been controlled for several days. Therapy may be initiated with a single dose of sterile triamcinolone acetonide suspension veterinary in which case the tablet dosage should be administered beginning 5 to 7 days after the injection or when symptoms reappear.
Limitations
The labeling shall comply with the requirements of 510.410 of this chapter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Vetalog Cream

SPL · SPL

Open original
FDA Structured Product Label

Vetalog Cream

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Boehringer Ingelheim Animal Health USA Inc.
NADA
46146
Status
RX
Form
Cream
Route
Topical
Species
Dog, No Use Class Stated Or Implied
Composition / specifications
Triamcinolone acetonide cream contains 0.1 percent triamcinolone acetonide in an aqueous vanishing cream base.

Dogs

Indication
The drug is recommended for use on dogs as an anti-inflammatory, antipruritic, and antiallergic agent for topical treatment of allergic dermatitis and summer eczema.
Dosage
The drug is applied by rubbing into affected areas two to four times daily for 4 to 10 days.
Limitations
For use only by or on the order of a licensed veterinarian.

Vetalog Oral Powder

SPL · SPL

Open original
FDA Structured Product Label

Vetalog Oral Powder

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Boehringer Ingelheim Animal Health USA Inc.
NADA
99388
Status
RX
Form
Powder
Route
Oral
Species
Horse, Not For Meat Production
Composition / specifications
Each 15 grams of triamcinolone acetonide oral powder contains 10 milligrams of triamcinolone acetonide.

Horses

Indication
The drug is used as an anti-inflammatory agent.
Dosage
It is administered at a dosage of 0.005 to 0.01 milligram triamcinolone acetonide per pound of body weight twice daily, sprinkled (top-dressed) on a small portion of feed. Treatment may be initiated with a single dose of sterile triamcinolone acetonide suspension USP followed after 3 or 4 days with the use of triamcinolone acetonide oral powder.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption.

Triamcinolone Acetonide Suspension

SPL · SPL

Open original
FDA Structured Product Label

Triamcinolone Acetonide Suspension

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Cronus Pharma Specialities India Private Ltd.
NADA
138-869
Status
RX
Form
Liquid (Suspension)
Route
Intramuscular, Intra-Articular, Intrasynovial, Subcutaneous, Intralesional
Species
Dog, Restricted During Pregnancy • Horse, Not For Meat Production • Cat, Restricted During Pregnancy
Composition / specifications
Each milliliter of suspension contains 2 or 6 milligrams triamcinolone acetonide.

Horses

Indication
Treatment of inflammation and related disorders.
Dosage
Single injection of 0.01 to 0.02 milligrams intramuscularly or subcutaneously per pound of body weight. Usual dose, 12 to 20 milligrams intramuscularly or subcutaneously. Or administer single injection of 6 to 18 milligrams intra-articularly and intrasynovially dose dependent on size of joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage may be increased not to exceed 18 milligrams intra-articularly and intrasynovially.
Limitations
Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Not for use in horses intended for food. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Do not use in the treatment of laminitis. Intra-articular injection in equine leg injuries may produce osseous metaplasia. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Cats

Indication
Treatment of inflammation and related disorders and management and treatment of acute arthritis and allergic and dermatologic disorders.
Dosage
Single injection of 0.05 to 0.1 milligrams intramuscularly or subcutaneously per pound of body weight in inflammatory, arthritic or allergic disorders. Single injection of 0.1 milligrams intramuscularly or subcutaneously per pound of body weight in dermatologic disorders. If symptoms recur the dose may be repeated, or oral corticosteroid therapy may be instituted. Or administer 1.2 to 1.8 milligrams intralesionally, divided in several injections, spaced around the lesion at 0.5 to 2.5 centimeters apart depending on the size. At any one site the dose injected should not exceed 0.6 milligrams intralesionally and should be well into the cutis to prevent rupture of the epidermis. When treating animals with multiple lesions, do not exceed a total dose of 6 milligrams intralesionally. Or administer a single injection of 1 to 3 milligrams intra-articularly and intrasynovially, dependent on size of joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage exceed 3 milligrams intra-articularly and intrasynovially.
Limitations
Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Dogs

Indication
Treatment of inflammation and related disorders and management and treatment of acute arthritis and allergic and dermatologic disorders.
Dosage
Single injection of 0.05 to 0.1 milligrams intramuscularly or subcutaneously per pound of body weight in inflammatory, arthritic or allergic disorders. Single injection of 0.1 milligrams intramuscularly or subcutaneously per pound of body weight in dermatologic disorders. If symptoms recur the dose may be repeated, or oral corticosteroid therapy may be instituted. Or administer 1.2 to 1.8 milligrams intralesionally, divided in several injections, spaced around the lesion at 0.5 to 2.5 centimeters apart depending on the size. At any one site the dose injected should not exceed 0.6 milligrams intralesionally and should be well into the cutis to prevent rupture of the epidermis. When treating animals with multiple lesions, do not exceed a total dose of 6 milligrams intralesionally. Or administer a single injection of 1 to 3 milligrams intra-articularly and intrasynovially, dependent on size of joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage exceed 3 milligrams intra-articularly and intrasynovially.
Limitations
Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Vetalog® Parenteral

SPL · SPL

Open original
FDA Structured Product Label

Vetalog® Parenteral

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Boehringer Ingelheim Animal Health USA, Inc.
NADA
12198
Status
RX
Form
Liquid (Suspension)
Route
Intramuscular, Intralesional, Intra-Articular, Subcutaneous, Intrasynovial
Species
Dog, Restricted During Pregnancy • No Use Class Stated Or Implied • Cat, Restricted During Pregnancy
Composition / specifications
Each milliliter of suspension contains 2 or 6 milligrams triamcinolone acetonide.

Dogs

Indication
Treatment of inflammation and related disorders in dogs; and management and treatment of acute arthritis and allergic and dermatologic disorders in dogs.
Dosage
Intramuscular or subcutaneous: Single injection of 0.05 to 0.1 milligram per pound of body weight in inflammatory, arthritic or allergic disorders. Single injection of 0.1 milligram per pound of body weight in dermatologic disorders. If symptoms recur the dose may be repeated, or oral corticosteroid therapy may be instituted. Intralesional: 1.2 to 1.8 milligrams, divided in several injections, spaced around the lesion at 0.5 to 2.5 centimeters apart depending on the size. At any one site the dose injected should not exceed 0.6 milligrams and should be well into the cutis to prevent rupture of the epidermis. When treating animals with multiple lesions, do not exceed a total dose of 6 milligrams. Intra-articular and intrasynovial: Single injection of 1 to 3 milligram dose, dependent on size of joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage exceed 3 milligrams.
Limitations
Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Horses

Indication
Treatment of inflammation and related disorders in horses.
Dosage
Intramuscular or subcutaneous: Single injection of 0.01 to 0.02 milligrams per pound of body weight. Usual dose, 12 to 20 milligrams. Intra-articular and intrasynovial: Single injection of 6 to 18 milligram dose dependent on size of joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage may be increased not to exceed 18 milligrams.
Limitations

Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Do not use in horses intended for human consumption. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Do not use in the treatment of laminitis. Intra-articular injection in equine leg injuries may produce osseous metaplasia. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental da

Indication
Treatment of inflammation and related disorders in cats; and management and treatment of acute arthritis and allergic and dermatologic disorders in cats.
Dosage
Intramuscular or subcutaneous: Single injection of 0.05 to 0.1 milligram per pound of body weight in inflammatory, arthritic or allergic disorders. Single injection of 0.1 milligram per pound of body weight in dermatologic disorders. If symptoms recur the dose may be repeated, or oral corticosteroid therapy may be instituted. Intralesional: 1.2 to 1.8 milligrams, divided in several injections, spaced around the lesion at 0.5 to 2.5 centimeters apart depending on the size. At any one site the dose injected should not exceed 0.6 milligrams and should be well into the cutis to prevent rupture of the epidermis. When treating animals with multiple lesions, do not exceed a total dose of 6 milligrams. Intra-articular and intrasynovial: Single injection of 1 to 3 milligram dose, dependent on size of joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage exceed 3 milligrams.
Limitations
Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Vetalog®

SPL · SPL

Open original
FDA Structured Product Label

Vetalog®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Boehringer Ingelheim Animal Health USA, Inc.
NADA
137-694
Status
RX
Form
Tablet
Route
Oral
Species
Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
Each tablet contains 0.5 and 1.5 milligrams of the drug.

Cats

Indication
The drug is indicated for anti-inflammatory activity.
Dosage
An initial daily dosage of 0.05 milligram per pound of body weight is usually sufficient to control symptoms, although up to 0.1 milligram per pound of body weight may be given daily if response to the smaller dose is inadequate. As soon as feasible, and in any case within 2 weeks, dosage should be reduced gradually to maintenance levels of 0.0125 to 0.025 milligram per pound of body weight per day.
Limitations
Therapy should be discontinued by a gradual reduction in dosage after the condition has been controlled for several days. Therapy may be initiated with a single dose of sterile triamcinolone acetonide suspension veterinary in which case the tablet dosage should be administered beginning 5 to 7 days after the injection or when symptoms reappear. The labeling shall comply with the requirements of 510.410 of this chapter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Dogs

Indication
The drug is indicated for anti-inflammatory activity.
Dosage
An initial daily dosage of 0.05 milligram per pound of body weight is usually sufficient to control symptoms, although up to 0.1 milligram per pound of body weight may be given daily if response to the smaller dose is inadequate. As soon as feasible, and in any case within 2 weeks, dosage should be reduced gradually to maintenance levels of 0.0125 to 0.025 milligram per pound of body weight per day.
Limitations
Therapy should be discontinued by a gradual reduction in dosage after the condition has been controlled for several days. Therapy may be initiated with a single dose of sterile triamcinolone acetonide suspension veterinary in which case the tablet dosage should be administered beginning 5 to 7 days after the injection or when symptoms reappear. The labeling shall comply with the requirements of 510.410 of this chapter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

VETAZINE

SPL · SPL

Open original
FDA Structured Product Label

VETAZINE

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Modern Veterinary Therapeutics, LLC
ANADA
200-459
Form
Cream
Route
Topical
Species
Dog, No Use Class Stated Or Implied
Composition / specifications
1 mg of triamcinolone acetonide per gram

Dogs

Indication
For topical treatment of allergic dermatitis and summer eczema in dogs.
Dosage
Apply by rubbing into the affected areas two to four times daily for 4 to 10 days.

Genesis® Topical Spray

SPL · SPL

Open original
FDA Structured Product Label

Genesis® Topical Spray

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Virbac AH, Inc.
NADA
141-210
Status
RX
Form
Liquid (Solution)
Route
Topical
Species
Dog, No Use Class Stated Or Implied
Composition / specifications
Each milliliter of solution contains 0.15 milligrams (0.015%) triamcinolone acetonide.

Dogs

Indication
For the control of pruritus associated with allergic dermatitis.
Dosage
Apply sufficient pump sprays to uniformly and thoroughly wet the affected areas while avoiding run off of excess product. Administer twice daily for 7 days, then once daily for 7 days, then every other day for an additional 14 days (28 days total).
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. For topical use in dogs only.

Genesis SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Genesis. Use the source link for the full official labeling record.

Triamcinolone acetonide SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Triamcinolone acetonide. Use the source link for the full official labeling record.

ucm061703.pdf

FOI · FOI

Open original

N138869_Org_1_6_1987..pdf

FOI · FOI

Open original

ucm117775.pdf

FOI · FOI

Open original

N140810_Org_5_31_1988.pdf

FOI · FOI summary

Open original

ucm061671.pdf

FOI · FOI summary

Open original

ucm061795.pdf

FOI · FOI summary

Open original

N140879_Org_8_2_1989.pdf

FOI · FOI summary

Open original

N140847_Org_9_30_1988.pdf

FOI · FOI summary

Open original
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Storefront facts: Source Roxee | Refreshed May 5, 2026, 10:00 AM UTC
    The storefront fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: Genesis Triamcinolone acetonide
Manufacturer mapping: Multiple FDA labelers
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Cat, Dog, Horse, No Use Class Stated Or Implied
Rx/OTC: RX
Form/route: Cream, Liquid (Solution), Liquid (Suspension), Powder, Tablet • Intra-Articular, Intralesional, Intramuscular, Intrasynovial, Oral, Subcutaneous, Topical
Applications: ANADA 200-275 • NADA 13624 • NADA 46146 • NADA 99388 • NADA 138-869 • NADA 12198 • NADA 137-694 • ANADA 200-459 • NADA 141-210
NDC: Packages 51311-105-08 51311-105-16 73309-105-01 • Products 51311 73309
Documents: 3 (FOI: 3) • SPL: 9 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 5 • Cat 0 • View
Case summaries: 1 (showing 1) • View
openFDA reports are unverified and do not prove causation.
Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95), Fda_Label (0.95)
Diagnosis Codes

Diagnosis-code mappings are not available for this medication yet.

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Do not use in horses intended for human consumption. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Do not use in the treatment of laminitis. Intra-articular injection in equine leg injuries may produce osseous metaplasia. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For mild inflammations, use once daily to once a week. For severe conditions, apply initially two to three times daily, decreasing frequency as improvement occurs. Not intended for treatment of deep abscesses or deep-seated infections. Not for ophthalmic use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Contraindication, High)
Top reaction signals
Tiredness (lethargy) (1) Miosis (1) Medication error NOS (1) Incorrect route of drug administration (1) Hiding (1) Head shake - behavioural disorder (1) Foam in the mouth (1) Eye disorder NOS (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
ANADA: 200245 ANADA: 200275 ANADA: 200330 ANADA: 200459 NADA: 12198 NADA: 12258 NADA: 13624 NADA: 137694 NADA: 138869 NADA: 140810 NADA: 140847 NADA: 140879 NADA: 140889 NADA: 141003 NADA: 141210 NADA: 30045 NADA: 46146 NADA: 96676 NADA: 99388 NDC Package: 17033-122-15 NDC Package: 17033-122-30 NDC Package: 17033-122-75 NDC Package: 51311-105-08 NDC Package: 51311-105-16
Package NDC Product NDC Form / Route Status
17033-122-15 17033 -
17033-122-30 17033 -
17033-122-75 17033 -
51311-105-08 51311 -
51311-105-16 51311 -
73309-105-01 73309 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

  • Genesis SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Triamcinolone acetonide SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • N140810_Org_5_31_1988.pdf • FOI summary • Official • Jan. 21, 2025
    FDA FOI summary for application 140810
  • ucm061703.pdf • FOI summary • Official • Dec. 26, 2023
    FDA FOI summary for application 200275
  • ucm061671.pdf • FOI summary • Official • Dec. 26, 2023
    FDA FOI summary for application 200245
  • N138869_Org_1_6_1987..pdf • FOI summary • Official • Feb. 1, 2018
    FDA FOI summary for application 138869
  • ucm061795.pdf • FOI summary • Official • Dec. 27, 2017
    FDA FOI summary for application 200330
  • N140879_Org_8_2_1989.pdf • FOI summary • Official • May 17, 2017
    FDA FOI summary for application 140879
  • N140847_Org_9_30_1988.pdf • FOI summary • Official • May 17, 2017
    FDA FOI summary for application 140847
  • ucm117775.pdf • FOI summary • Official • June 1, 2016
    FDA FOI summary for application 141210

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 45 Clinical 1 Manufacturer 0 Marketing 0
Current Field Facts
  • side_effects: Top reported reactions (openFDA): Deafness, Loss of hearing, Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Lack of efficac… (Clinical, 2026-04-11)
  • contraindications: Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic ne… (Official, 2026-04-12)
  • contraindications: Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic ne… (Official, 2026-04-11)
  • contraindications: Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic ne… (Official, 2026-02-12)
  • indications: For the control of pruritus associated with allegic dermatitis in dogs. Medalone Cream (Triamcinolone Acetonide Cream) is indicated for topical treatment of al… (Official, 2026-05-05)
  • indications: For the control of pruritus associated with allegic dermatitis in dogs. Medalone Cream (Triamcinolone Acetonide Cream) is indicated for topical treatment of al… (Official, 2026-05-03)
  • indications: For the control of pruritus associated with allegic dermatitis in dogs. Medalone Cream (Triamcinolone Acetonide Cream) is indicated for topical treatment of al… (Official, 2026-05-02)
  • indications: For the control of pruritus associated with allegic dermatitis in dogs. Medalone Cream (Triamcinolone Acetonide Cream) is indicated for topical treatment of al… (Official, 2026-04-29)
  • indications: For the control of pruritus associated with allegic dermatitis in dogs. Medalone Cream (Triamcinolone Acetonide Cream) is indicated for topical treatment of al… (Official, 2026-04-28)
  • indications: For the control of pruritus associated with allegic dermatitis in dogs. Medalone Cream (Triamcinolone Acetonide Cream) is indicated for topical treatment of al… (Official, 2026-04-27)
  • indications: For the control of pruritus associated with allegic dermatitis in dogs. Medalone Cream (Triamcinolone Acetonide Cream) is indicated for topical treatment of al… (Official, 2026-04-26)
  • indications: For the control of pruritus associated with allegic dermatitis in dogs. Medalone Cream (Triamcinolone Acetonide Cream) is indicated for topical treatment of al… (Official, 2026-04-25)
  • indications: For the control of pruritus associated with allegic dermatitis in dogs. Medalone Cream (Triamcinolone Acetonide Cream) is indicated for topical treatment of al… (Official, 2026-04-22)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-05-05)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-05-03)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-05-02)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-04-29)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-04-28)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-04-27)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-04-26)
Recent Revisions
  • side_effects updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Medalone Cream
RX
Triamcinolone Acetonide
Cream • Topical
Label highlights
Official documents
Med-Pharmex, Inc. ANADA 200-275 W Dec 26, 2023
Triamcinolone Acetonide
RX
Triamcinolone Acetonide
Tablet • Oral
Label highlights
Official documents
Boehringer Ingelheim Animal Health USA Inc. NADA 13624 W May 3, 2023
Vetalog Cream
RX
Triamcinolone Acetonide
Cream • Topical
Label highlights
Official documents
Boehringer Ingelheim Animal Health USA Inc. NADA 46146 W May 3, 2023
Vetalog Oral Powder
RX
Triamcinolone Acetonide
Powder • Oral
Label highlights
Official documents
Boehringer Ingelheim Animal Health USA Inc. NADA 99388 W May 3, 2023
Triamcinolone Acetonide Suspension
RX
Triamcinolone Acetonide
Liquid (Suspension) • Intramuscular, Intra-Articular, Intrasynovial, Subcutaneous, Intralesional
Label highlights
Official documents
Cronus Pharma Specialities India Private Ltd. NADA 138-869 Approved Feb 1, 2018
Vetalog® Parenteral
RX
Triamcinolone Acetonide
Liquid (Suspension) • Intramuscular, Intralesional, Intra-Articular, Subcutaneous, Intrasynovial
Label highlights
Official documents
Boehringer Ingelheim Animal Health USA, Inc. NADA 12198 Approved Jan 9, 2018
Vetalog®
RX
Triamcinolone Acetonide
Tablet • Oral
Label highlights
Official documents
Boehringer Ingelheim Animal Health USA, Inc. NADA 137-694 Approved Feb 23, 2017
VETAZINE
Triamcinolone Acetonide
Cream • Topical
Label highlights
Official documents
Modern Veterinary Therapeutics, LLC ANADA 200-459 W Aug 16, 2016
Genesis® Topical Spray
RX
Triamcinolone Acetonide
Liquid (Solution) • Topical
Label highlights
Official documents
Virbac AH, Inc. NADA 141-210 Approved Jun 1, 2016

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
Triamcinolone acetonide cream contains 0.1 percent triamcinolone acetonide in an aqueous vanishing cream base.
Dogs
Indication
The drug is recommended for use on dogs as an anti-inflammatory, antipruritic, and antiallergic agent for topical treatment of allergic dermatitis and summer eczema.
Dosage
The drug is applied by rubbing into affected areas two to four times daily for 4 to 10 days.
Limitations
For use only by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
Each tablet contains 0.5 and 1.5 milligrams of the drug.
Dogs
Indication
The drug is indicated for use in dogs for its anti-inflammatory activity.
Dosage
An initial daily dosage of 0.05 milligram per pound of body weight is usually sufficient to control symptoms, although up to 0.1 milligram per pound of body weight may be given daily if response to the smaller dose is inadequate. As soon as feasible, and in any case within 2 weeks, dosage should be reduced gradually to maintenance levels of 0.0125 to 0.025 milligram per pound of body weight per day. Therapy should be discontinued by a gradual reduction in dosage after the condition has been controlled for several days. Therapy may be initiated with a single dose of sterile triamcinolone acetonide suspension veterinary in which case the tablet dosage should be administered beginning 5 to 7 days after the injection or when symptoms reappear.
Limitations
The labeling shall comply with the requirements of 510.410 of this chapter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Cats
Indication
The drug is indicated for use in cats for its anti-inflammatory activity.
Dosage
An initial daily dosage of 0.05 milligram per pound of body weight is usually sufficient to control symptoms, although up to 0.1 milligram per pound of body weight may be given daily if response to the smaller dose is inadequate. As soon as feasible, and in any case within 2 weeks, dosage should be reduced gradually to maintenance levels of 0.0125 to 0.025 milligram per pound of body weight per day. Therapy should be discontinued by a gradual reduction in dosage after the condition has been controlled for several days. Therapy may be initiated with a single dose of sterile triamcinolone acetonide suspension veterinary in which case the tablet dosage should be administered beginning 5 to 7 days after the injection or when symptoms reappear.
Limitations
The labeling shall comply with the requirements of 510.410 of this chapter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
Triamcinolone acetonide cream contains 0.1 percent triamcinolone acetonide in an aqueous vanishing cream base.
Dogs
Indication
The drug is recommended for use on dogs as an anti-inflammatory, antipruritic, and antiallergic agent for topical treatment of allergic dermatitis and summer eczema.
Dosage
The drug is applied by rubbing into affected areas two to four times daily for 4 to 10 days.
Limitations
For use only by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Horse, Not For Meat Production
Composition / specifications
Each 15 grams of triamcinolone acetonide oral powder contains 10 milligrams of triamcinolone acetonide.
Horses
Indication
The drug is used as an anti-inflammatory agent.
Dosage
It is administered at a dosage of 0.005 to 0.01 milligram triamcinolone acetonide per pound of body weight twice daily, sprinkled (top-dressed) on a small portion of feed. Treatment may be initiated with a single dose of sterile triamcinolone acetonide suspension USP followed after 3 or 4 days with the use of triamcinolone acetonide oral powder.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, Restricted During Pregnancy • Horse, Not For Meat Production • Cat, Restricted During Pregnancy
Composition / specifications
Each milliliter of suspension contains 2 or 6 milligrams triamcinolone acetonide.
Horses
Indication
Treatment of inflammation and related disorders.
Dosage
Single injection of 0.01 to 0.02 milligrams intramuscularly or subcutaneously per pound of body weight. Usual dose, 12 to 20 milligrams intramuscularly or subcutaneously. Or administer single injection of 6 to 18 milligrams intra-articularly and intrasynovially dose dependent on size of joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage may be increased not to exceed 18 milligrams intra-articularly and intrasynovially.
Limitations
Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Not for use in horses intended for food. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Do not use in the treatment of laminitis. Intra-articular injection in equine leg injuries may produce osseous metaplasia. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Cats
Indication
Treatment of inflammation and related disorders and management and treatment of acute arthritis and allergic and dermatologic disorders.
Dosage
Single injection of 0.05 to 0.1 milligrams intramuscularly or subcutaneously per pound of body weight in inflammatory, arthritic or allergic disorders. Single injection of 0.1 milligrams intramuscularly or subcutaneously per pound of body weight in dermatologic disorders. If symptoms recur the dose may be repeated, or oral corticosteroid therapy may be instituted. Or administer 1.2 to 1.8 milligrams intralesionally, divided in several injections, spaced around the lesion at 0.5 to 2.5 centimeters apart depending on the size. At any one site the dose injected should not exceed 0.6 milligrams intralesionally and should be well into the cutis to prevent rupture of the epidermis. When treating animals with multiple lesions, do not exceed a total dose of 6 milligrams intralesionally. Or administer a single injection of 1 to 3 milligrams intra-articularly and intrasynovially, dependent on size of joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage exceed 3 milligrams intra-articularly and intrasynovially.
Limitations
Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Dogs
Indication
Treatment of inflammation and related disorders and management and treatment of acute arthritis and allergic and dermatologic disorders.
Dosage
Single injection of 0.05 to 0.1 milligrams intramuscularly or subcutaneously per pound of body weight in inflammatory, arthritic or allergic disorders. Single injection of 0.1 milligrams intramuscularly or subcutaneously per pound of body weight in dermatologic disorders. If symptoms recur the dose may be repeated, or oral corticosteroid therapy may be instituted. Or administer 1.2 to 1.8 milligrams intralesionally, divided in several injections, spaced around the lesion at 0.5 to 2.5 centimeters apart depending on the size. At any one site the dose injected should not exceed 0.6 milligrams intralesionally and should be well into the cutis to prevent rupture of the epidermis. When treating animals with multiple lesions, do not exceed a total dose of 6 milligrams intralesionally. Or administer a single injection of 1 to 3 milligrams intra-articularly and intrasynovially, dependent on size of joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage exceed 3 milligrams intra-articularly and intrasynovially.
Limitations
Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, Restricted During Pregnancy • No Use Class Stated Or Implied • Cat, Restricted During Pregnancy
Composition / specifications
Each milliliter of suspension contains 2 or 6 milligrams triamcinolone acetonide.
Dogs
Indication
Treatment of inflammation and related disorders in dogs; and management and treatment of acute arthritis and allergic and dermatologic disorders in dogs.
Dosage
Intramuscular or subcutaneous: Single injection of 0.05 to 0.1 milligram per pound of body weight in inflammatory, arthritic or allergic disorders. Single injection of 0.1 milligram per pound of body weight in dermatologic disorders. If symptoms recur the dose may be repeated, or oral corticosteroid therapy may be instituted. Intralesional: 1.2 to 1.8 milligrams, divided in several injections, spaced around the lesion at 0.5 to 2.5 centimeters apart depending on the size. At any one site the dose injected should not exceed 0.6 milligrams and should be well into the cutis to prevent rupture of the epidermis. When treating animals with multiple lesions, do not exceed a total dose of 6 milligrams. Intra-articular and intrasynovial: Single injection of 1 to 3 milligram dose, dependent on size of joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage exceed 3 milligrams.
Limitations
Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Horses
Indication
Treatment of inflammation and related disorders in horses.
Dosage
Intramuscular or subcutaneous: Single injection of 0.01 to 0.02 milligrams per pound of body weight. Usual dose, 12 to 20 milligrams. Intra-articular and intrasynovial: Single injection of 6 to 18 milligram dose dependent on size of joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage may be increased not to exceed 18 milligrams.
Limitations

Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Do not use in horses intended for human consumption. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Do not use in the treatment of laminitis. Intra-articular injection in equine leg injuries may produce osseous metaplasia. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental da
Indication
Treatment of inflammation and related disorders in cats; and management and treatment of acute arthritis and allergic and dermatologic disorders in cats.
Dosage
Intramuscular or subcutaneous: Single injection of 0.05 to 0.1 milligram per pound of body weight in inflammatory, arthritic or allergic disorders. Single injection of 0.1 milligram per pound of body weight in dermatologic disorders. If symptoms recur the dose may be repeated, or oral corticosteroid therapy may be instituted. Intralesional: 1.2 to 1.8 milligrams, divided in several injections, spaced around the lesion at 0.5 to 2.5 centimeters apart depending on the size. At any one site the dose injected should not exceed 0.6 milligrams and should be well into the cutis to prevent rupture of the epidermis. When treating animals with multiple lesions, do not exceed a total dose of 6 milligrams. Intra-articular and intrasynovial: Single injection of 1 to 3 milligram dose, dependent on size of joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage exceed 3 milligrams.
Limitations
Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
Each tablet contains 0.5 and 1.5 milligrams of the drug.
Cats
Indication
The drug is indicated for anti-inflammatory activity.
Dosage
An initial daily dosage of 0.05 milligram per pound of body weight is usually sufficient to control symptoms, although up to 0.1 milligram per pound of body weight may be given daily if response to the smaller dose is inadequate. As soon as feasible, and in any case within 2 weeks, dosage should be reduced gradually to maintenance levels of 0.0125 to 0.025 milligram per pound of body weight per day.
Limitations
Therapy should be discontinued by a gradual reduction in dosage after the condition has been controlled for several days. Therapy may be initiated with a single dose of sterile triamcinolone acetonide suspension veterinary in which case the tablet dosage should be administered beginning 5 to 7 days after the injection or when symptoms reappear. The labeling shall comply with the requirements of 510.410 of this chapter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Dogs
Indication
The drug is indicated for anti-inflammatory activity.
Dosage
An initial daily dosage of 0.05 milligram per pound of body weight is usually sufficient to control symptoms, although up to 0.1 milligram per pound of body weight may be given daily if response to the smaller dose is inadequate. As soon as feasible, and in any case within 2 weeks, dosage should be reduced gradually to maintenance levels of 0.0125 to 0.025 milligram per pound of body weight per day.
Limitations
Therapy should be discontinued by a gradual reduction in dosage after the condition has been controlled for several days. Therapy may be initiated with a single dose of sterile triamcinolone acetonide suspension veterinary in which case the tablet dosage should be administered beginning 5 to 7 days after the injection or when symptoms reappear. The labeling shall comply with the requirements of 510.410 of this chapter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
1 mg of triamcinolone acetonide per gram
Dogs
Indication
For topical treatment of allergic dermatitis and summer eczema in dogs.
Dosage
Apply by rubbing into the affected areas two to four times daily for 4 to 10 days.
Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
Each milliliter of solution contains 0.15 milligrams (0.015%) triamcinolone acetonide.
Dogs
Indication
For the control of pruritus associated with allergic dermatitis.
Dosage
Apply sufficient pump sprays to uniformly and thoroughly wet the affected areas while avoiding run off of excess product. Administer twice daily for 7 days, then once daily for 7 days, then every other day for an additional 14 days (28 days total).
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. For topical use in dogs only.

FDA page: Open in Animal Drugs @ FDA

Usage

Treatment of inflammation and related disorders in dogs; and management and treatment of acute arthritis and allergic and dermatologic disorders in dogs. Treatment of inflammation and related disorders in horses. Treatment of inflammation and related disorders in cats; and management and treatment of acute arthritis and allergic and dermatologic disorders in cats.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Do not use in horses intended for human consumption. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Do not use in the treatment of laminitis. Intra-articular injection in equine leg injuries may produce osseous metaplasia. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For mild inflammations, use once daily to once a week. For severe conditions, apply initially two to three times daily, decreasing frequency as improvement occurs. Not intended for treatment of deep abscesses or deep-seated infections. Not for ophthalmic use. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Vomiting (1) • Cat Drooling (1) • Dog Diarrhea (1) • Cat Appetite loss (1) • Dog

Showing top 5 for Digestive.

Skin & allergy
Localised hair loss (1) • Dog

Showing top 5 for Skin & allergy.

Neurologic
Tiredness (1) • Cat Head tilt - neurological disorder (1) • Cat

Showing top 5 for Neurologic.

Behavior
Head shake - behavioural disorder (1) • Cat Behavioral disorder (1) • Cat

Showing top 5 for Behavior.

Effectiveness
Lack of efficacy - NOS (1) • Dog

Showing top 5 for Effectiveness.

Other
Moist dermatitis (1) • Dog Miosis (1) • Cat Medication error NOS (1) • Dog Licking at application site (1) • Dog Incorrect route of drug administration (1) • Dog
Show more (17)
Inappropriate urination (1) • Dog Hiding (1) • Cat Foam in the mouth (1) • Dog Fever (1) • Cat Eye disorder NOS (1) • Cat Eardrum rupture (1) • Cat Ear infection NOS (1) • Dog Ear discharge (1) • Cat Dry skin (1) • Dog Deafness (1) • Dog Cyanosis (1) • Dog Breathing difficulty (1) • Dog Blindness (1) • Cat Application site scratching (1) • Dog Anaphylaxis (1) • Dog Accidental exposure (1) • Dog Abnormal breathing (1) • Cat

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Bulldog - French, Female, 3 year, 10.795 kilogram • Drug: MSK, Parenteral • Reactions: Vomiting, Breathing difficulty, Cyanosis, Urinary incontinence, Anaphylaxis • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-071520
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 3.00 Year
  • Weight: 10.795 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Parenteral
Reactions Reported:
Vomiting Breathing difficulty Cyanosis Urinary incontinence Anaphylaxis
Outcomes: Recovered/Normal

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.